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ABSTRACT 
The development of a generic liposomal doxorubicin product requires the study of critical physicochemical properties of the formulation. Food and 
Drug Administration (FDA) draft guideline has suggested few parameters to be tested for in vitro bioequivalence study which include liposomal 
composition, state of encapsulated drug, internal environment, liposomal morphology and number of lamellae, lipid bilayer phase transition, 
liposomal size distribution, grafted Polyethylene Glycol (PEG) at liposomal surface, electric surface potential or charge and in vitro leakage under 
multiple conditions. Characteristic features of components of liposomal doxorubicin formulation and detail of parameters to be studied have been 
discussed. This review compile specific, current and historical research outcomes on in vitro analysis of liposomal doxorubicin and highlights the 
important features that have a critical impact on properties of liposomal doxorubicin formulation. It will provide a better insight to the generic 
manufacturers and will help them to identify the critical quality attributes during the formulation development phase.  
Keywords: Bioequivalence, Doxorubicin, Liposome, Critical, Attributes 
© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open-access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijap.2020v12i2.35330. Journal homepage: https://innovareacademics.in/journals/index.php/ijap  
 
INTRODUCTION 
Doxorubicin is a member of the anthracycline class of antineoplastic 
drugs and is effective in a variety of solid tumours and hematological 
malignancies [1]. Doxorubicin (Dox) hydrochloride (C27H29NO4
The therapy-limiting toxicity for this drug is cardiomyopathy, which 
may lead to congestive heart failure and death. Around 2% of 
patients who have received Dox experience of this condition. As the 
usage of Dox is limited to its dose-related cardiotoxicity and 
myelosuppression, the liposomal form of Dox is beneficial due to its 
superior efficacy and minimum cardiotoxicity [3, 4]. Some of the 
commonly available liposomal based doxorubicin products are 
DOXIL, CAELYX and MYOCET. DOXIL was one of the first drugs to be 
approved that is delivered using liposome as a carrier [5]. Maryam 
et al. (2019) have made attempts to reduce the toxicity of 
doxorubicin by co-administering it with PEGylated liposomal 
galbanic acid (PLGba) as it could improve the outcome of the 
chemotherapy even with a reduced dose of PEGylated liposomal 
doxorubicin (PLD) [6]. Suchismita et al. (2019) formulated 
controlled release doxorubicin in the nanocomposite form using 
graphene grafted with chitosan and polyaniline aiming to reduce the 
toxicity [7]. Srikanth et al. (2019) have formulated doxorubicin 
proniosomes to reduce the systemic toxicity of the drug [8].  
) is a 
high molecular weight compound (579.98 gm/mol) and is isolated 
from Streptomyces peucetius. It was first introduced in the 1970s, 
and since then it has become one of the most commonly used drugs 
for the treatment of both hematological and solid tumors [2]. 
DOXIL/Caelyx has a longer circulation lifetime which is due to the 
steric barrier provided by the surface-grafted PEG, which leads to 
large changes in bio-distribution and particularly increased amounts 
of drug being delivered to the skin. This has advantages for the 
treatment of skin localized cancers such as Kaposi’s sarcoma but 
disadvantages in the observation of new dose-limiting toxicities 
such as hand and foot syndrome [9]. 
While designing liposomal formulations of Doxorubicin, the 
following criteria’s are kept in mind: (a) Doxorubicin is released 
from the liposomes following intravenous administration, (b) The 
distribution of doxorubicin following administration of a liposomal 
formulation is dependent on the biodistribution characteristics of 
the liposomes, and (c) The biological activity of liposomal 
doxorubicin is dependent on when, where, and at what rate the drug 
is released. So a prerequisite knowledge of the chemical and physical 
properties and the mechanism (s) of action of this drug, is necessary 
before formulation [10]. Naozumi et al. (2008) has studied different 
in vitro parameters of liposomal formulations formed with egg 
phosphatidylcholine (EPC) as phospholipid and combination of EPC 
and hydrogenated soya phosphatidylcholine (HSPC) as lipid 
components and compared them with those of DOXIL [11]. 
Doxorubicin is an amphipathic molecule possessing a water-
insoluble aglycone (adriamycinone: C21H18 O9) and a water-soluble, 
basic, reducing amino-sugar moiety (daunosamine: C6H13 NO3
 
). 























Fig. 1: Structure of doxorubicin 
 
Doxorubicin has anti-mitotic and cytotoxic activity through the 
formation of complexes with DNA by intercalation between base 
pairs. It also inhibits topoisomerase II activity by stabilizing the 
DNA-topoisomerase II complex, preventing the religation portion of 
the ligation-religation reaction that topoisomerase II catalyzes [1]. 
Doxorubicin and its major metabolite, doxorubicinol, is 74-76% 
bound to plasma protein. The extent to binding is independent of 
plasma concentration up to 1.1 mcg/ml. Doxorubicin does not cross 
the blood-brain barrier. 
Doxorubicin is capable of undergoing metabolism via 3 metabolic 
routes: one-electron reduction, two-electron reduction and 
deglycosylation.  
However, approximately half of the dose is eliminated from the body 
unchanged. Two electron reduction is the primary metabolic 
pathway and it yields doxorubicinol, secondary alcohol [12]. 
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FDA guideline for in vitro testing 
FDA draft guideline gives recommendations regarding the in vitro 
bioequivalence study of injectable liposomal doxorubicin 
hydrochloride for product development and quality control of a 
generic formulation.  
FDA’s draft guidance for bioequivalence study mentions some of the 
following parameters which are to be studied. They are: liposomal 
composition, state of encapsulated drug, internal environment, 
liposomal morphology and number of lamellae, lipid bilayer phase 
transition, liposomal size distribution, grafted PEG at the liposomal 
surface, electric surface potential or charge and in vitro leakage 
under multiple conditions [13].  
Liposomal composition 
In liposomal composition following components are to be evaluated 
(a) Lipid content, (b) free and encapsulated drug, (c) internal and 
total sulfate and ammonium concentration, (d) histidine 
concentration and sucrose concentration [13]. Drug-to-lipid ratio 
and the percentage of drug encapsulation can be calculated from 
liposome composition values.  
Reports show a strong association of liposomal composition and 
cytotoxicity and the key factor involved for this is the cellular uptake 
of the liposomes. PEGylation decreases the intracellular uptake of 
liposomes and consequently reduces cellular toxicity. Acyl chain 
length of lipid component influenced the release rate, cytotoxicity 
increases with short acyl chains as there is an increase in the release 
of doxorubicin with short acyl chains [14].  
DOXIL/Caelyx liposomal formulation contains hydrogenated soya 
phosphatidylcholine (HSPC), cholesterol (Chol) and PEG-modified 
phosphatidylethanolamine in 55:40:5 molar ratio whereas Myocet 
has a different composition as it contains egg phosphatidylcholine 
(EPC) and Chol in 55:45 molar ratio [15]. 
Long and fully saturated acyl chains of HSPC confers tight packing of 
bilayer structure which helps liposomes for better retention due to 
very low permeability. 
Cholesterol eliminates the phase transition of the phospholipids that 
helps to reduce the permeability of the liposome bilayer to ions and 
small polar molecules at a temperature range which is critical to the 
drug loading step during the manufacturing process. Concentration 
of cholesterol must be sufficient in the bilayer to achieve good drug 
loading and retention. 
Microbubbles coated polyethylene glycol-di-stearoyl phosphatidyl-
ethanolamine (MPEG-DSPE) chain confers the "stealth" property to 
the liposomes. Approximately 5% of MPEG-DSPE (on the basis of 
molar ratio) is present in DOXIL. Product with less than 2% MPEG-
DSPE showed diminished "stealth" property hence, altered 
pharmacokinetics [12]. Structures of MPEG-DSPE and HSPC are 
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Fig. 3: Structure of HSPC (Hydrogenated soybean phosphatidylcholine) 
 
Mordente et al. (2009) studied and found that the presence of 
ammonium sulfate at optimal concentration inside the liposomes 
before the drug loading step is important to achieve high drug 
loading efficiency [12]. In addition, the sulfate inside of the 
liposomes complexes with doxorubicin to form a precipitate and is 
integral to drug retention and drug release. 
Cersosimo et al. (1989) found that ion concentrations in a liposome 
helps to establish a stable and efficient drug encapsulation process. 
Ammonium ion controls not only the efficiency of the drug loading 
process, stability of the product and drug release profile of the 
product. Normal amounts of ammonia for a healthy adult range 
0.5~1×10-4
In vitro leakage testing 
 M, excess ammonia can potentially lead to severe 
neurodevelopmental and neurodegenerative complications [16-19].  
Doxorubicin liposomes are designed to retain doxorubicin during 
circulation and minimize clearance by the mononuclear phagocyte 
system and also limit uptake in healthy tissue. Table 1 shows the test 
conditions recommended by FDA to study the leakage from liposomal 
doxorubicin. 
Factors affecting the release rate 
There are several factors that can affect the release rate. Reported 
studies showed that only 10% drug is released in 50% plasma in 
normal saline at 37 °C after 48 h which could be due to insufficient 
temperature as the release rate is very low. Release in phosphate 
buffer solution (at all pH) was observed to be higher than the release 
rate in McLlvaine buffer. Release rate further increased with an 
increase in dilution. Effect of ultrasound radiation was due to 
temporary disruption of lipid layer causing rapid release of the drug 
but with an amplitude-dependent manner. Ultrasound also causes 
an increase in the particle size.  
Shibata et al. (2015) reported that physical stability of bilayer, chemical 
stability of phospholipids, solubility of drug encapsulated in the 
liposomes affect the drug release from the liposomes. Increase in the 
concentration of lysophospholipids and free fatty acids was found to 
have a clear pH dependence but ultrasound irradiation does not cause an 
increase in the concentrations of lysophospholipids or free fatty acids. 
When the concentration of lysophospholipids and free fatty acids is 
12.5% of total lipids or more permeability of lipid bilayer and hence 
release rates have been found to increase synergistically at pH 5.5 [20]. 
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In a study, conducted by Luo et al. (2016), it was found that Near 
Infrared radiation (NIR) triggered the release of doxorubicin (Dox) 
was achieved by including 2 molar % porphyrin-phospholipid (PoP) 
from conventional sterically stabilized stealth liposomes [21]. 
 
Table 1: Different conditions along with reasons for testing of drug leakage 
Conditions Reasons In vivo organ which it simulates References 
At 37 °C in 50% human plasma for 
24 h. 
Evaluate liposome stability 
in blood circulation. 
Plasma mostly mimics blood conditions.  
 
[13] 
At 37 °C with pH values 5.5, 6.5, 
and 7.5 for 24 h in the buffer. 
 
Mimic drug release in 
normal tissues, around 
cancer cells, or inside cancer 
cells. 
 
Normal tissues: pH 7.3  
Cancer tissues: pH 6.6  
Insider cancer cells (endosomes and lysosomes): pH 5–6 
(endosome and lysosomes of cancer cells may be involved in 
liposome uptake and induce drug release).  
[13] 
At a range of temperatures (43, 
47, 52 and 57 °C) in pH 6.5 buffer 
for up to 12 h or until complete 
release. 
Evaluate the lipid bilayer 
integrity. 
 
The Tm of lipids is determined by lipid bilayer properties such 
as rigidity, stiffness and chemical composition. Differences in 
the release as a function of temperature (below or above Tm) 
will reflect small differences in lipid properties.  
[13] 
At 37 °C under low-frequency (20 
kHz) ultrasound for 2 h or until 
complete release. 
Evaluate the state of the 
encapsulated drug in the 
liposome. 
 
Low-frequency ultrasound (20 kHz) disrupts the lipid bilayer 
via a transient introduction of pore-like defects and will render 
the release of doxorubicin controlled by the dissolution of the 
gel inside the liposome.  
[13] 
 
State of doxorubicin 
Doxorubicin is commonly found as a salt form such as sulfate, citrate 
etc., in the liposomes. Electron microscopy images showed that 
doxorubicin sulphate containing liposomes were ellipsoidal 
containing dark stripes. X ray diffraction pattern showed by Lasic et 
al. (1992) has a single sharp reflection at 27 Å which states that the 
DOX-sulphate interfibre spacing is 27 Å [22]. 
In another study on doxorubicin citrate, cryo-Transmission Electron 
Microscopy (TEM) images showed an interfibre spacing for DOX-
citrate to be 30-35 Å. NMR studies on 13
Studies carried by Xingong et al. (1998) showed that interfibre space 
difference may be due to the fact that sulphate is a small ion than 
citrate. DOX-citrate showed different patterns were observed such 
as hexagonal arrangement, U-shaped arrangement, circular bundles 
and fibrous bundles with repeating units after 50 nm [23]. 
C-citrate revealed that there 
exists a dynamic interaction between Dox-citrate with the rapid 
exchange of free and bound citrate.  
In contrast DOX-sulphate aggregates were noted as only straight 
bundles in DOX-sulphate.  
Internal volume 
The internal environment of a liposome mainly includes volume, pH, 
sulfate and ammonium concentration helps to maintain the 
precipitated doxorubicin [14].  
Entrapment efficiency is directly related to the internal volume. 





It is an important parameter to measure the morphology of liposomes 
[24, 25]. In a study it that relatively low volume of entrapped aqueous 
space per mole of lipid was observed in the case of both MLV 
(multilamellar vesicles) and SUV which results in restricted ability to 
encapsulate large macromolecules. In MLV most of the lipid is 
participating in the internal lamellae, and there is a restriction of the 
internal water space due to the close apposition of the concentric 
adjacent bilayers. In case of SUV, which are single-compartment 
vesicles, due to large ratio of surface area to encapsulated volume only 
a small aqueous volume per mole of lipid can be attained [26]. 
Techniques such as reverse phase evaporation have been developed 
to prepare liposomes such that a large percentage of aqueous 
materials can be entrapped in the internal volume [27]. 
Internal pH  
Liposomes are usually prepared by pH gradient method either by 
using citrate buffer or ammonium sulfate buffer. The internal pH 
was reported to be around 4 in the case of both citrate and 
ammonium sulfate buffers and was stable for at least 20 d [28]. 
Internal pH has an effect on the stability of the drug. Liposomal 
system loaded with curcumin was developed with an acidic internal 
microenvironment pH has an effect on chemical stability and 
anticancer activity [29]. 
Number lamellae and degree of lamellarity 
PEGylated liposomal doxorubincin is an oval-shaped and unilamellar 
liposome [30]. It is important to study lamellarity as the extent the 
encapsulation efficiency, drug retention, the efflux rate of 
liposomally encapsulated material, and the fate of a drug after 
cellular uptake depends greatly on the lamellarity of liposomes [31, 
13]. The degree of lamellarity refers to the number of lipid bilayers 
in a liposome. A liposome may have a single lipid bilayer, or multiple 
concentric lipid bilayers. Studies show that DOXIL has 
approximately 1 to 2% multilamellarity, the remaining 98 to 99% of 
the liposomes have only a single lipid bilayer. When multilamellar 
vesicles percentage is high, entrapped volume significantly 
decreases which results in lower drug-to lipid ratio. The net effect is 
that lower drug is loaded in the liposomes which leads to lower 
efficiency and higher toxicity. Lower drug release rate has been 
found in multi-lamellar vesicles as the drug has to pass larger 
number of lipid bilayer barriers before reaching to the external 
phase of the liposomes [32].  
Particle size distribution 
D50 and Polydispersity index (PDI) given as (D90–D10)/D50 is 
usually calculated using the population bioequivalence approach 
(PBE). It is also required to be measured according to the FDA draft 
guideline along with particle size distribution. To describe the 
particle size distribution of liposome [33].  
The particle size and PDI of nanocarrier systems have a strong 
influence on the endocytosis-dependent cellular uptake.  
Particles smaller than 50 nm can interact with hepatocytes, while 
particles larger than 1 μm are absorbed by mononuclear phagocytes 
as emboli [34]. 
It has been found that nanocarriers with particle size less than 150 
nm are able to cross the fenestrated capillaries in the tumor 
microenvironment. Tumors have leaky vasculature which allows 
accumulation of high molecular weight therapeutics in them. This 
effect is known as the enhanced permeability and retention (EPR) 
effect. Through this, circulating nanocarriers with size less than 
around 150 nm extravasate from the circulation and accumulates 
within the tumour [35-38]. In some literature, the size below 200 
nm has been mentioned. Reports have shown that by decreasing the 
diameter size of the liposomes to 50 nm or below reduced 
mononuclear phagocyte system (MPS)-mediated clearance in mice 
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models with comparable a plasma half-life as of long-circulating 
(PEGylated) vesicles with a diameter of 100–150 nm [39-40]. 
Lipid bilayer phase transition 
The gel to the liquid-crystalline phase transition of the lipid bilayer 
can be determined by differential scanning calorimetery (DSC) and it 
provides information about bilayer fluidity and uniformity, drug 
interactions with the lipid bilayer and liposome formation [41]. The 
fluidity of lipid bilayer depends on the TC which is the chain melting 
transition temperature. Phospholipid exists in different states above 
and below TC
Presence of cholesterol has been reported to enhance the mechanical 
stability of the membrane. Studies carried by Lorena et al. (2012) 
showed that low cholesterol contents lead to a phase-segregated system 
but high cholesterol contents gives a homogeneous bilayer [42]. 
.  
PEG grafted 
Standard liposome formulations such as Caelyx® (DOXIL® in the United 
States) are coated with polyethylene (PEG) which is a synthetic 
hydrophilic polymer. The bulky PEG head group serves as a barrier 
preventing interactions with plasma opsonins, hence, it retards 
recognition by the reticuloendothelial system and slowing elimination of 
the liposomes from circulation. These PEG-coated liposomes are known 
as sterically stabilized or STEALTH liposomes (fig. 4) [43].  
 
MPEG-DSPE coating




Fig. 4: Structure of stealth lipososme, *
 
MPEG: Microbubbles 
coated Poly ethylene glycol, DSPE: Distearoyl phosphatidyl 
ethanolamine 
Greater than 90% of the drug is encapsulated as STEALTH liposomes 
[23]. 
Jianwei et al. (2018) co-encapsulated doxorubicin and verapamil 
into gold liposomes to overcome the multi-drug resistance as 
verapamil inhibits multi drug resistance protein [44].  
PEG grafts can be present in two different configurations: as a 
random coil grafted in one end (“mushroom”) or as an 
approximately linear polymer (“brush”). 
Surface PEG conformation (mushroom or brush conformation) 
determination was based on the calculated ratio of the Flory 
dimension (R f
R
) to the average distance between adjacent PEG chains 
(D). PEG Flory dimension and the distance between surface grafted 
PEG chains were calculated using the given equation.  
f  = aN
Where a is PEG monomer size in Å (previously reported as 3.8 Å 






A is the PEG area per lipid molecule in the bilayer (previously 
reported as 67 Å2 [46]) and M is the mole fraction of PEG lipid 
determined experimentally as described above R f
Electric surface potential or charge 
/D values 
calculated below 1.0 indicates a mushroom regime, while those 
above 1.0 indicate brush [47].  
Surface charge (zeta potential) on liposomes has a significant effect 
on the clearance, tissue distribution and cellular uptake.  
Cancer cell surfaces are usually charged negatively due to the 
translocation of negatively charged constituents of the inner layer of 
the cell membrane (e. g., phosphatidylserine, anionic phospholipids, 
glycoproteins and proteoglycans), the cationic liposomal 
doxorubicin (LPs-DOX) will have increased uptake due to better 
interaction between negatively charged cancer cells and positively 
charged (LPs-DOX) [48].  
A strong linear relationship was noted between zeta potential values 
and the mole percentage of charged lipids within a liposome [49]. 
Negatively charged liposomes have been reported to be 
immunostimulant but zwitterionic ones were not. [50-51]. 
CONCLUSION 
Parameters for in vitro bioequivalence study for generic product 
development of liposomal doxorubicin have been described in FDA 
draft guideline. The review helps to understand the importance of 
each physicochemical parameter critical for the formulation of a 
liposomal form of doxorubicin. Role of each component has been 
described which will be useful in formulation development scientist 
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